We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Proposed Rule Changes Names of Zarxio, Neupogen, Four Other Biologicals
Proposed Rule Changes Names of Zarxio, Neupogen, Four Other Biologicals
Just days before Sandoz is expected to launch Zarxio, its biosimilar of Amgen’s chemotherapy drug Neupogen, the FDA issued a proposed rule changing both drugs’ official names, at least temporarily.